MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
14.78
+0.54
+3.79%
Opening 15:29 05/20 EDT
OPEN
14.32
PREV CLOSE
14.24
HIGH
15.17
LOW
14.28
VOLUME
30.83K
TURNOVER
0
52 WEEK HIGH
30.40
52 WEEK LOW
3.000
MARKET CAP
1.26B
P/E (TTM)
-0.7173
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GYRE last week (0513-0517)?
Weekly Report · 9h ago
Gyre Therapeutics, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 6d ago
Weekly Report: what happened at GYRE last week (0506-0510)?
Weekly Report · 05/13 10:05
Gyre Therapeutics GAAP EPS of $0.03, revenue of $27.12M
Seeking Alpha · 05/10 13:06
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q1 2024
Gyre Therapeutics just reported results for the first quarter of 2024. The company reported earnings per share of 3 cents and revenue of $27.17 million. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports. Gyre TherAPEutics reported earnings of 3cents per share.
Investorplace · 05/10 02:54
Gyre Therapeutics Q1 EPS $0.03, Same YoY, Sales $27.17M Up From $24.93M YoY
Benzinga · 05/09 21:24
GYRE THERAPEUTICS INC: QTRLY DILUTED SHR $0.03
Reuters · 05/09 20:10
GYRE THERAPEUTICS INC: U.S. IND SUBMISSION TO EVALUATE F351 FOR TREATMENT OF NASH-ASSOCIATED LIVER FIBROSIS EXPECTED IN LATE 2024
Reuters · 05/09 20:10
More
About GYRE
Gyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in the research, development, manufacturing and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase III trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase I trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.